Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola Schmitt

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|May 10, 2014
Can a treatment be licenced on the basis of post-treatment predictive biomarkers?Andrew Stone, Nicola Schmitt
Journal of the American Academy of Audiology|May 15, 2016
A Phoneme Perception Test Method for High-Frequency Hearing Aid FittingNicola Schmitt, Alexandra Winkler, Michael Boretzki, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2015
Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionalsEsther Bettiol, Jeffrey D Wetherington, Nicola Schmitt, et al.
The Journal of the Acoustical Society of America|December 3, 2017
Predicting effects of hearing-instrument signal processing on consonant perceptionJohannes Zaar, Nicola Schmitt, Ralph-Peter Derleth, et al.
Molecules (Basel, Switzerland)|October 6, 2015
Metabolic Profiling of Alpine and Ecuadorian LichensVerena K Mittermeier, Nicola Schmitt, Lukas P M Volk, et al.
Cancer|April 23, 2013
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemiaHagop M Kantarjian, Giovanni Martinelli, Elias J Jabbour, et al.
Critical Care Medicine|December 17, 2013
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*Gordon R Bernard, Bruno Francois, Jean-Paul Mira, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|May 10, 2014
Can a treatment be licenced on the basis of post-treatment predictive biomarkers?Andrew Stone, Nicola Schmitt
Journal of the American Academy of Audiology|May 15, 2016
A Phoneme Perception Test Method for High-Frequency Hearing Aid FittingNicola Schmitt, Alexandra Winkler, Michael Boretzki, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2015
Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionalsEsther Bettiol, Jeffrey D Wetherington, Nicola Schmitt, et al.
The Journal of the Acoustical Society of America|December 3, 2017
Predicting effects of hearing-instrument signal processing on consonant perceptionJohannes Zaar, Nicola Schmitt, Ralph-Peter Derleth, et al.
Molecules (Basel, Switzerland)|October 6, 2015
Metabolic Profiling of Alpine and Ecuadorian LichensVerena K Mittermeier, Nicola Schmitt, Lukas P M Volk, et al.
Cancer|April 23, 2013
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemiaHagop M Kantarjian, Giovanni Martinelli, Elias J Jabbour, et al.
Critical Care Medicine|December 17, 2013
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*Gordon R Bernard, Bruno Francois, Jean-Paul Mira, et al.
Pageof 1